Contraceptives: Opportunity Analysis and Forecasts to 2027

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Hormonal contraceptives are primarily used to prevent unintended pregnancy; however, some of these contraceptives are also approved or used off-label for other health conditions, particularly menstrual-related disorders. This report focuses on female hormonal contraceptives used for birth control as well as other non-contraceptive benefits distinct from their ability to prevent pregnancy. Female hormonal contraceptives are used in women of reproductive age, which according to the World Health Organization (WHO) refers to all women ages 15–49 years.
GlobalData estimates the 2017 sales for the contraceptives market at approximately $6.34 billion across the 8MM, encompassing the US, the five major European countries (5EU: France, Germany, Italy, Spain, and UK), Japan, and China. By 2027, GlobalData expects the overall market to grow at a moderate compound annual growth rate (CAGR) of 2.7% to reach sales of $8.24 billion over the 10-year period. The Chinese market is anticipated to grow the fastest, recording a CAGR of 6.2%, while the US, 5EU, and Japan will each record CAGRs of 4.8%, -0.5%, and -1.1%, respectively. At the end of 2027, the US will contribute around 63.5% of global sales, while the 5EU, Japan, and China will account for 78.6%, 16.7%, and 4.7% of global sales, respectively.
Key Questions Answered
Combination oral contraceptives (COCs) have dominated the contraceptives market for many years. However, there has been an increased usage of other contraceptive routes of administration, such as hormonal intrauterine devices (IUDs), vaginal rings, and subcutaneous implants. What are the treatment trends during the forecast period? What factors do women take into account when choosing a contraceptive?
There are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the contraceptives market?
How will the entrance of the five late stage pipeline drugs affect the global contraceptive treatment landscape?

Scope

Overview of contraceptives, including patterns of treatment, unmet needs and opportunity, current treatment landscape, pipeline drug analysis, and R&D strategies.

Annualized contraceptives market revenue, annual cost of therapy and treatment usage pattern data from 2017 and forecast for ten years to 2027.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the contraceptives market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global contraceptives market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

Develop business strategies by understanding the trends shaping and driving the global contraceptives market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global contraceptives market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the global contraceptives market from 2017-2027.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Agile Therapeutics
Allergan
Antares Pharma Bayer
ContraMed
Exeltis Germany
Evofem Biosciences
Fuji Pharma Co.
Merck
Mithra Pharmaceuticals
Pfizer
The Population Council
Sebela Pharma
Therapeutics MD
Viramal Ltd

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Contraceptives: Executive Summary

2.1 Moderate Growth in the Contraceptives Market Is Expected Between 2017 and 2027, Driven by US and China Sales

2.2 Developers Targeting Other Female Health Conditions in Addition to Contraception

2.3 The Contraceptives Market Is Still in Need of Therapeutics with Better Safety Profiles

2.4 Significant Opportunity Remains in Chinese and Japanese Contraceptives Markets

2.5 The Diverse Late-Stage Pipeline Offers Women More Options for Contraception

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Contraception

4.2 Other Indications

5 Current Treatment Options

5.1 Overview

6 Unmet Needs and Opportunity Assessment

6.1 Overview

6.2 Hormonal Contraceptives with Reduced Adverse Reactions

6.3 Non-hormonal Contraceptives

6.4 Better Compliance and Adherence to Contraceptives

6.5 Access to a Wide Range of Contraceptive Methods

6.6 Awareness of Different Contraceptive Methods

7 R&D Strategies

7.1 Overview

7.1.1 Development of Novel Non-hormonal Contraceptives

7.1.2 Utilization of Contraceptives for Other Disease Indications

7.1.3 New Drug Delivery Technologies

7.2 Clinical Trials Design

7.2.1 Pearl Index as an Efficacy Tool

7.2.2 Selection of an Active Comparator

8 Pipeline Assessment

8.1 Overview

8.2 Innovative Early-Stage Approaches

9 Pipeline Valuation Analysis

9.1 Clinical Benchmark of Key Pipeline Drugs

9.2 Commercial Benchmark of Key Pipeline Drugs

9.3 Competitive Assessment

9.4 Top-Line 10-Year Forecast

9.4.1 US

9.4.2 5EU

9.4.3 Japan

9.4.4 China

10 Appendix

10.1 Bibliography

10.2 Abbreviations

10.3 Methodology

10.3.1 Forecasting Methodology

10.3.2 Percent Drug-Treated Patients

10.3.3 Drugs Included in Each Therapeutic Class

10.3.4 Launch and Patent Expiry Dates

10.3.5 General Pricing Assumptions

10.3.6 Individual Drug Assumptions

10.3.7 Generic Erosion

10.3.8 Pricing of Pipeline Agents

10.4 Primary Research – KOLs Interviewed for This Report

10.5 Primary Research – Prescriber Survey

10.6 About the Authors

10.6.1 Senior Analyst

10.6.2 Managing Analyst

10.6.3 Therapy Area Director

10.6.4 Global Director of Therapy Analysis and Epidemiology

10.6.5 Global Head and EVP of Healthcare Operations and Strategy

10.7 About GlobalData

10.8 Contact Us

10.9 Disclaimer

Table

Table 1: Contraceptives: Key Metrics in the 8MM

Table 2: Most Common Types of Contraceptives

Table 3: Leading Currently Marketed Branded Contraceptives, 2017

Table 4: Comparison of Therapeutic Classes in Development for Contraception, 2017–2027

Table 5: Innovative Early-Stage Approaches for Contraception, 2018

Table 6: Clinical Benchmark of Key Pipeline Drugs – Contraceptives

Table 7: Commercial Benchmark of Key Pipeline Drugs – Contraceptives

Table 8: Key Events Impacting Sales for Contraceptives, 2017–2027

Table 9: Contraceptives Market – Global Drivers and Barriers, 2017–2027

Table 10: Key Historical and Projected Launch Dates for Contraceptives

Table 11: Key Historical and Projected Patent Expiry Dates for Contraceptives

Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

Figures

Figure 1: Global Sales Forecast by Country for Contraceptives in 2017 and 2027

Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against Oral Contraceptives

Figure 3: Unmet Needs and Opportunities in Contraceptives

Figure 4: Overview of the Development Pipeline in Contraception

Figure 5: Key Phase II/III Trials for the Promising Pipeline Agents That GlobalData Expects to Be Licensed for Contraception in the 8MM During the Forecast Period

Figure 6: Competitive Assessment of the Pipeline Drugs Benchmarked Against Oral Contraceptives

Figure 7: Global (8MM) Sales Forecast by Country for Contraceptives in 2017 and 2027

Figure 8: Global Sales Forecast by Class for Contraceptives in 2017 and 2027

Frequently asked questions

Contraceptives: Opportunity Analysis and Forecasts to 2027 standard reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Contraceptives: Opportunity Analysis and Forecasts to 2027 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Contraceptives: Opportunity Analysis and Forecasts to 2027 in real time.

  • Access a live Contraceptives: Opportunity Analysis and Forecasts to 2027 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.